NCT07598448尚未招募不适用
Clinical Experience With Iptacopan in Adult Patients With Complement 3 Glomerulopathy (C3G): A Multicenter, Observational, Retrospective Study of Patients Treated Through an Early Access Program in Spain
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 35
研究概览
简要总结
This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients (≥18 years).
- •Biopsy-confirmed C3G.
- •Patients who have received at least one dose of iptacopan through an EAP from October 2020 to June 2025.
排除标准
- •1. Patients treated with iptacopan through an EAP for indications other than C3G.
研究组 & 干预措施
Iptacopan Cohort
Adult patients with C3G who received iptacopan through an EAP in Spain.
研究者
相似试验
招募中
3 期
Study to assess the pharmacokinetics, safety, and tolerability of iptacopan in pediatric PNH patients2024-515926-10-00Novartis Pharma AG5
招募中
不适用
Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic MicroangiopathyThrombotic MicroangiopathyNCT07347990First Affiliated Hospital of Zhejiang University30
招募中
2 期
A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis.2023-510525-15-00Novartis Pharma AG44
招募中
4 期
A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with primary IgA nephropathy2023-508690-92-00Novartis Pharma AG100
已完成
3 期
A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopan2022-502148-10-00Novartis Pharma AG25